Chinese pharmaceutical company Guiyang Xintian Pharmaceutical has announced the pricing for its proposed initial public offering (IPO) of shares to raise ¥317.02m ($46m) in gross proceeds.
Under the IPO, the company will issue 17.22 million shares priced at ¥18.41 ($2.67) each.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
US-based biopharmaceutical company TetraGenetics has announced that it has secured venture funding from JDRF T1D Fund in order to expedite the development of a type 1 diabetes immunotherapy.
Magenta Therapeutics has completed a series B financing round to raise $50m, which will be utilised to develop product candidates in transplantation medicines used for a more precise preparation of patients, as well as stem cell harvesting and expansion.
Magenta Therapeutics is a biotechnology company based in the US.
ImCheck Therapeutics has raised €20m ($21.8m) in a series A venture financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners and Idinvest Partners, and participated in by Gimv NV and Life Sciences Partners.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBased in France, ImCheck Therapeutics develops biotherapies for immune-oncology.
The proceeds from the venture financing round are intended to be used to advance the development of a number of drug candidates and begin clinical trials by 2018.
US-based pulmonary drug developer Savara intends to raise $18m in gross proceeds through a public offering of shares.
The proceeds are intended to be used for working capital and general corporate purposes.
